Changes in Hong Kong stocks | Insili Intelligence (03696) rose more than 5% and plans to repurchase up to HK$500 million in the open market ISM6331 positive data was recently published in ESMO

The Zhitong Finance App learned that Insili Intelligence (03696) rose by more than 5%. As of press release, it had risen 4.67% to HK$37.68, with a turnover of HK$248 million.

According to the news, on October 30, Insilicon Smart announced that the Company has decided to repurchase the Company's shares on the Hong Kong Stock Exchange Limited (Stock Exchange) open market from time to time in accordance with the general mandate (repurchase authorization) granted to directors at the Annual General Meeting of Shareholders held on June 2, 2026 and approved by the Company's shareholders, for a total amount of up to HK$500 million (share repurchase). The board of directors believes that the current transaction price of shares undervalues the company's intrinsic value and development prospects, and that share buybacks will increase shareholder value. The share repurchase reflects the company's confidence in its business prospects and development, and will benefit the company and create value for its shareholders in the long run.

Recently, Insili Intelligence issued an announcement stating that the company recently announced preliminary positive data from the first human phase I clinical trial of ISM6331. ISM6331 is an oral pan-TEAD inhibitor under research designed with the help of the Chemistry42 generative AI platform. The findings were presented as a quick oral report at the 2026 European Society of Medical Oncology (ESMO) Annual Meeting in Madrid, Spain. In preclinical studies, ISM6331 showed a wide range of anti-tumor efficacy, strong activity at low doses, ideal safety, and good ADMET characteristics. Previously, in July 2026, ISM6331 obtained FDA Fast Track eligibility.